5,098 Shares in Molina Healthcare, Inc $MOH Acquired by Evolve Private Wealth LLC

Evolve Private Wealth LLC purchased a new stake in Molina Healthcare, Inc (NYSE:MOH) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 5,098 shares of the company’s stock, valued at approximately $1,166,000.

A number of other large investors have also modified their holdings of the stock. BlackRock Inc. acquired a new position in Molina Healthcare during the 2nd quarter worth approximately $1,503,052,000. AQR Capital Management LLC increased its holdings in Molina Healthcare by 217.0% in the third quarter. AQR Capital Management LLC now owns 2,934,130 shares of the company’s stock valued at $561,475,000 after buying an additional 2,008,458 shares during the last quarter. 8 Knots Management LLC acquired a new stake in Molina Healthcare in the fourth quarter valued at $198,942,000. Maverick Capital Ltd. acquired a new stake in Molina Healthcare in the first quarter valued at $86,081,000. Finally, Madison Avenue Partners LP purchased a new stake in Molina Healthcare during the 4th quarter worth about $110,003,000. Hedge funds and other institutional investors own 98.50% of the company’s stock.

Molina Healthcare Trading Up 0.2%

Shares of NYSE MOH opened at $200.63 on Monday. Molina Healthcare, Inc has a 12-month low of $121.06 and a 12-month high of $244.89. The company has a market cap of $10.47 billion, a price-to-earnings ratio of -1,114.55, a price-to-earnings-growth ratio of 28.70 and a beta of 0.75. The company has a current ratio of 1.68, a quick ratio of 1.68 and a debt-to-equity ratio of 0.95. The stock’s 50 day simple moving average is $211.25 and its 200 day simple moving average is $178.56.

Molina Healthcare (NYSE:MOH) last issued its quarterly earnings data on Wednesday, July 22nd. The company reported $1.51 earnings per share for the quarter, beating the consensus estimate of $1.39 by $0.12. Molina Healthcare had a negative net margin of 0.02% and a positive return on equity of 3.73%. The firm had revenue of $10.87 billion for the quarter, compared to the consensus estimate of $10.83 billion. During the same period last year, the firm posted $5.48 EPS. Molina Healthcare’s quarterly revenue was down 4.8% compared to the same quarter last year. Equities research analysts expect that Molina Healthcare, Inc will post 5.29 EPS for the current year.

Wall Street Analysts Forecast Growth

MOH has been the subject of a number of research reports. Jefferies Financial Group set a $230.00 price target on shares of Molina Healthcare in a research report on Tuesday, July 14th. Mizuho set a $215.00 price objective on Molina Healthcare in a research report on Monday, June 8th. Bank of America raised Molina Healthcare from an “underperform” rating to a “buy” rating and set a $250.00 price objective on the stock in a research report on Wednesday, April 29th. Weiss Ratings lowered shares of Molina Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, July 24th. Finally, JPMorgan Chase & Co. increased their target price on Molina Healthcare from $169.00 to $191.00 and gave the company a “neutral” rating in a research note on Monday, June 8th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $202.44.

Molina Healthcare Company Profile

Molina Healthcare, Inc is a managed care company specializing in government-sponsored health insurance programs. The company offers Medicaid managed care plans, Medicare Advantage and prescription drug plans, and individual Marketplace plans under the Affordable Care Act. Through an integrated care model, Molina emphasizes preventive and primary care services, care coordination, and disease management to improve health outcomes for its members.

The company traces its roots to the early 1980s, when Dr.